NEW YORK, March 16 (GenomeWeb News) - Cellzome today said that it will collaborate with Johnson & Johnson Pharmaceutical Research & Development, an affiliate of Ortho-McNeil Pharmaceutical, in a drug-discovery research program for Alzheimer's disease.
Â
Cellzome will apply its chemical proteomics technology to the program, and will receive a technology-access fee and research funding for two years. The company said it is also eligible for development milestone payments.
Â
Ortho-McNeil will have exclusive worldwide rights to products developed during the collaboration and will pay Cellzome royalties on sales. J&JPRD will support the discovery research conducted at Cellzome, while Ortho-McNeil will be responsible for development, manufacturing, and commercialization of any drugs that result from the collaboration.
Â
Cellzome said it will provide access to its existing Alzheimer's program technology, which includes an amyloid precursor protein processing pathway map and new drug targets. Ortho-McNeil will also have an option to license Cellzome's Gamma Secretase Modulator program, which Cellzome said includes novel small molecules for development as orally active treatments.